Published in Int J Mol Sci on December 04, 2015
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | NCT01829971
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel) (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Identification of novel genes coding for small expressed RNAs. Science (2001) 44.44
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature (2000) 39.31
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Principles of microRNA-target recognition. PLoS Biol (2005) 23.70
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
RNA interference. Nature (2002) 22.28
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Evolution and functions of long noncoding RNAs. Cell (2009) 17.54
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res (2012) 15.41
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol (2008) 12.35
Non-coding RNA. Hum Mol Genet (2006) 10.57
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
Genome-wide transcription and the implications for genomic organization. Nat Rev Genet (2007) 9.45
Natural RNA circles function as efficient microRNA sponges. Nature (2013) 8.93
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell (2010) 6.94
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
The functional role of long non-coding RNA in human carcinomas. Mol Cancer (2011) 6.37
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
The let-7 family of microRNAs. Trends Cell Biol (2008) 6.24
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
The miR-34 family in cancer and apoptosis. Cell Death Differ (2009) 5.92
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J (1998) 5.70
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell (2010) 5.67
MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet (2012) 5.38
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends Genet (2005) 5.07
Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene (2010) 4.81
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer (2004) 4.59
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. J Urol (2013) 4.20
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene (2012) 3.83
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79
lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature (2013) 3.77
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One (2011) 3.59
MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57
An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A (2007) 3.54
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol (2003) 3.52
RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol (2013) 3.47
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res (2011) 3.38
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol (2008) 3.26
MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol (2002) 3.17
Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer (2011) 3.02
From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A (1999) 3.00
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A (2011) 2.89
Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol (2013) 2.84
Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer (2012) 2.74
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell (2012) 2.59
Identification of let-7-regulated oncofetal genes. Cancer Res (2008) 2.56
miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res (2009) 2.52
Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA (2014) 2.42
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res (2010) 2.39
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39
MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun (2009) 2.39
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A (2007) 2.34
PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A (2000) 2.17
PVT1 dependence in cancer with MYC copy-number increase. Nature (2014) 2.13
Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem (2001) 2.11
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer (2010) 2.08
MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res (2008) 2.03
Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci (2010) 2.03
miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res (2011) 2.02
Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A (2012) 2.02
Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene (2004) 2.02
Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov (2014) 2.00
Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 1.97
The central role of RNA in human development and cognition. FEBS Lett (2011) 1.92
Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol (2006) 1.90
The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res (2009) 1.88
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol (2014) 1.88
Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci (2009) 1.85
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun (2014) 1.84
Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol (2010) 1.82
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res (2011) 1.82